Growth & profitability
- Revenue has grown 35.4% per year over the past 5 years.
- Operating margin has expanded, at 50.1% in the latest year.
Financial health
- Total debt has grown slower than revenue (-1.9% vs 35.4% per year).
PTCT Financials Ptc Therapeutics, Inc.
15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $1.7B | $683M | 0.0% | 50.1% | -332.7% | 23.6% | $702M | — | $985M |
| 2024 | $807M | -$363M | 0.0% | -37.5% | 33.1% | -21.3% | -$114M | $285M | $780M |
| 2023 | $938M | -$627M | 0.0% | -46.9% | 76.5% | -33.1% | -$187M | $284M | $594M |
| 2022 | $699M | -$559M | 0.0% | -64.0% | 161.1% | -32.8% | -$389M | $572M | $280M |
| 2021 | $539M | -$524M | 0.0% | -69.5% | -36432.5% | -27.0% | -$280M | $431M | $190M |
| 2020 | $381M | -$438M | 0.0% | -113.4% | -90.9% | -19.8% | -$212M | $309M | $209M |
| 2019 | $307M | -$252M | 96.0% | -78.6% | -42.3% | -15.5% | -$112M | $314M | $288M |
| 2018 | $265M | -$128M | 95.2% | -43.7% | -36.5% | -11.4% | -$35M | $153M | $169M |
| 2017 | — | -$79M | — | — | -50.5% | -20.2% | -$13M | $145M | $112M |
| 2016 | — | -$142M | — | — | -118.8% | -52.8% | -$105M | $98M | $58M |
| 2015 | — | -$170M | — | — | -75.4% | -46.7% | -$127M | $92M | $58M |
| 2014 | — | -$94M | — | — | -31.4% | -28.1% | -$62M | — | $50M |
| 2013 | — | -$52M | — | — | -37.8% | -34.0% | — | — | $15M |
| 2012 | — | -$26M | — | — | 26.3% | -200.7% | — | $5M | $3M |
| 2011 | — | $31M | — | — | -13.0% | — | — | — | $28M |
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $361M | $83M | 0.0% | 41.3% | -50.5% | 2.6% | $127M | $591M | $1.0B |
| Mar '26 | $273M | -$3M | 0.0% | 16.5% | 1.6% | -0.1% | -$60M | — | $834M |
| Dec '25 | $165M | -$135M | 0.0% | -43.3% | 65.7% | -4.7% | -$37M | — | $985M |
| Sep '25 | $211M | $16M | 0.0% | 1.4% | -10.2% | 0.6% | -$70M | — | $673M |
| Jun '25 | $179M | -$65M | 0.0% | -19.5% | 31.4% | -2.5% | -$60M | $286M | $1.0B |
| Mar '25 | $1.2B | $867M | 0.0% | 82.5% | -466.5% | 32.6% | $868M | $286M | $1.5B |
| Dec '24 | $213M | -$66M | 0.0% | -76.2% | 6.0% | -3.9% | -$34M | $285M | $780M |
| Sep '24 | $197M | -$107M | 0.0% | -27.7% | 10.1% | -5.8% | -$78M | $285M | $526M |
| Jun '24 | $187M | -$99M | 0.0% | -21.5% | 10.1% | -5.2% | -$64M | $285M | $655M |
| Mar '24 | $210M | -$92M | 0.0% | -21.6% | 10.2% | -5.1% | $61M | $285M | $548M |
| Dec '23 | $307M | -$156M | 0.0% | 1.9% | 19.0% | -8.2% | -$106M | $284M | $594M |
| Sep '23 | $197M | -$133M | 0.0% | -60.1% | 19.8% | -10.6% | -$21M | $573M | $165M |
| Jun '23 | $214M | -$199M | 0.0% | -98.0% | 34.3% | -14.9% | -$20M | $573M | $208M |
| Mar '23 | $220M | -$139M | 0.0% | -53.4% | 30.4% | -8.6% | -$40M | $572M | $167M |
| Dec '22 | $167M | -$171M | 0.0% | -119.7% | 49.2% | -10.0% | -$175M | $572M | $280M |
| Sep '22 | $217M | -$109M | 0.0% | -31.4% | 48.2% | -6.9% | -$43M | $283M | $104M |
| Jun '22 | $166M | -$152M | 0.0% | -55.8% | 83.5% | -8.4% | -$64M | $432M | $158M |
| Mar '22 | $149M | -$127M | 0.0% | -58.2% | 139.9% | -7.0% | -$107M | $432M | $144M |
| Dec '21 | $165M | -$143M | 0.0% | -51.3% | -9962.8% | -7.4% | -$78M | $431M | $190M |
| Sep '21 | $139M | -$134M | 0.0% | -67.1% | -127.4% | -6.7% | -$57M | $431M | $190M |
Valuation over time
How the market has priced PTCT against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has fallen from 9.3× (Dec '25) to 8.7× (Sep '26).
- The price-to-sales ratio has fallen from 5.8× (Mar '23) to 3.4× (Sep '26).
P/E
P/S
Frequently asked questions
Is PTCT growing its revenue and profit?
Over the past 5 years, Ptc Therapeutics, Inc.'s revenue has grown 35.4% per year. These are computed facts, not advice.
How much debt does PTCT have?
As of FY2025, Ptc Therapeutics, Inc. reported — of total debt against $985M of cash.
What is PTCT's profit margin?
In FY2025, gross margin was —, operating margin 50.1%, and net margin 39.5%.
What is PTCT's P/E ratio?
As of Sep '26, Ptc Therapeutics, Inc. traded at a price-to-earnings ratio of about 8.7× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.